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AbstrAct
background and aim. There is a lack of recent epidemiological studies on recurrent stroke (RS) in Poland. The aim of this 
study was to analyse all hospitalisations related to RS in Silesia – an industrial region covering 12% of the Polish population.
Material and methods. We carried out statistical analysis of data contained in stroke questionnaires transferred to the 
Polish National Health Fund by hospitals in Silesia, Poland, between 2009 and 2015. 
results. In the analysed period, the number of RS hospitalisations in Silesia was 18,063 (22.2% of all acute strokes). The per-
centage of RS significantly decreased during the period under consideration (p < 0.001). The same observation concerned 
recurrent ischaemic stroke (RIS), but not recurrent haemorrhagic stroke (RHS). The median hospitalisation time was 14 days 
for RHS, and 11 days for RIS. Large-artery atherosclerosis and cardioembolisms were significantly more often recognised 
in RIS than in first-ever ischaemic stroke (FIS) (consecutively, 38.2% vs 36.0%, and 21% vs 18.1%; p < 0.001). The in-hospital 
mortality rate was significantly higher for RS than for first-ever stroke (18.4% vs 17.2%; p < 0.001). The same observation was 
done for RIS vs FIS (16.2% vs 13.9%; p < 0.001), and for RHS vs FHS (39.8% vs 36%; p = 0.004). The rtPA therapy was applied 
to 5.3% of FIS and 3.2% of RIS patients (p < 0.001).
conclusions. This is the first such comprehensive and long-term analysis of recurrent stroke in Silesia, Poland. It could help 
in the implementation of appropriate educational programmes, and thus help to improve the health status of society.
Key words: stroke, epidemiology, ischaemic stroke, haemorrhagic stroke, recurrent stroke
(Neurol Neurochir Pol 2019; 53 (4): 277–290)
Introduction
Stroke constitutes the third highest cause of death and 
the main cause of permanent disability in adults in Europe. 
Due to its poor prognosis, and the high costs of treatment 
and of chronic care, stroke is not only a medical but also 
a social problem. 
Recently conducted epidemiological studies have signi-
ficantly improved our understanding of stroke epidemiology 
and treatment. But regular updates at local, national and 
global levels are needed. The first epidemiological data on 
cerebrovascular diseases in Poland comes from the years 
1980–2010 [1–13]. The most recent studies, both national and 
regional, were conducted in the last decade [14–17]. Some 
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of them have concerned the Silesian Province, an industrial 
region of Poland covering 12% of the nation’s population 
(4.6 million people). In these studies, we have analysed the 
local incidence of first-ever-stroke (FS), the number of stroke 
hospitalisations, stroke aetiology, outcome, used methods of 
diagnostics, and treatment between 2009 and 2015 [15, 16]. 
However, there is still a  lack of recent epidemiological 
data on recurrent stroke (RS) in Poland despite the fact that 
this is a known indicator of the effectiveness of secondary 
stroke prevention. 
Therefore, the aim of this study was to assess the epidemio-
logical characteristics of RS in the Silesian Province of Poland 
over the course of the last decade.
Materials and methods
Our study was based on data obtained from stroke que-
stionnaires (n = 88,425) which were mandatorily reported to 
the National Health Fund (NHF; the only public health insurer 
in Poland) by all Silesian hospital departments for stroke pa-
tients (homogeneous patient groups: A48-A51). The analysed 
period was between 2009 and 2015. The study was carried out 
with the approval of the Silesian division of the NHF and the 
Consultant in Neurology for the Silesian Province. 
The questionnaire was verified for incomplete or recurring 
data (e.g. recurring records of the same hospitalisation were 
excluded). Finally, 81,193 stroke questionnaires were enrolled 
for analysis. A diagnosis of stroke was made according to the 
International Classification of Diseases version 10 (ICD-10).
The following data from the stroke questionnaires were 
used in the present study: age, sex, admission date, date of 
the first occurrence of stroke symptoms, date of death or 
discharge, number of hospitalisation days, aetiology of ischa-
emic stroke (IS) (according to the Trial Org 10172 in Acute 
Stroke Treatment - TOAST), clinical symptoms (consciousness 
disorders, hemiparesis/hemiplegia, speech disorders, senso-
ry disorders, posterior circle syndrome), secondary stroke 
prevention (antiplatelets, anticoagulants, antihypertensives), 
information on referral for vascular intervention due to artery 
stenosis, and application of recombinant tissue plasminogen 
activator (rtPA). 
The questionnaires also included information as to 
whether the stroke was classified as first-ever-stroke (FS) or 
recurrent stroke (RS). FS was diagnosed when the response 
to the question “Was it your first stroke accident?” was “Yes”, 
and RS when the response was “No”.
According to the Bioethics Committee, the study was not 
a medical experiment. Therefore, no approval of the Com-
mittee was required. 
Statistical analysis was done using SAS statistical package 
version 9.4 (SAS Institute Inc., Cary, NC, USA). The level of 
statistical significance was set at p < 0.05.
For nominal data, percentage values were used. The cor-
relation between the nominal variables was verified using the 
χ2 test. Normally distributed quantitative data were characte-
rised using the mean and the standard deviation, whereas the 
median and the interquartile range was used for non-normally 
distributed data. The verification of the distribution of the 
variables and the agreement with the normal distribution 
were made using the Shapiro-Wilk test. The mean difference 
significance was verified using the Student’s t-test for two 
groups and the ANOVA test for three or more groups. The 
consistency of the distribution was verified using the Mann-
-Whitney U test for two groups and the Kruskal-Wallis test 
for three or more groups for skewed distributions. Multiple 
comparisons were made based on post-hoc test results for 
variance analysis (ANOVA) and the Kruskal-Wallis test and 
with the Holm-Bonferroni correction to assess significance 
of the percentage difference in cases of three or more groups. 
The test for trend was also calculated for consecutive years by 
means of Jonckheere-Terpstra and Cochran-Armitage tests for 
continuous and categorical variables, respectively.
Results
Based on analysis of the data obtained from the stroke qu-
estionnaires, the number of RS hospitalisations in the Silesian 
Province between 2009 and 2015 was 18,063 (9,229 women 
and 8,715 men; P < 0.001; in 119 cases sex was not recorded). 
In 4,763 subjects, the type of stroke (first or recurrent) could 
not be determined (Tab. 1). 
RS constituted 22.2% of all acute stroke hospitalisations 
in the analysed period. The number of hospitalisations due 
to recurrent haemorrhagic stroke (RHS; I60, I61, I62) was 
1,619 (15% of all hospitalisations with acute haemorrhagic 
stroke i.e. HS diagnosis), while the total number of hospi-
talisations due to recurrent ischaemic stroke (RIS; I63) was 
16,256 (23.4% all hospitalisations with acute IS diagnosis) 
(Tab. 3, 4).
The percentage of RS significantly decreased during the 
period under consideration (p < 0.001). The same observation 
concerned RIS, but not RHS (Tab. 1, 3, 4). 
The median age for patients with RS was 74 (range 66–81) 
years. The age of male patients (71 (range 63–78) years) was 
statistically significantly lower (P < 0.001) compared to female 
patients (78 (70–84) years).
The median age for patients with RIS was 75 (range 66–81) 
years. The age of male patients (71 (range 63–79) years) was 
statistically significantly lower (P < 0.001) compared to female 
patients (78 (range 70–84) years).
The median age for patients with RHS was 72 (range 
62–80) years. The age of male patients (69 (range 61–77) years) 
was statistically significantly lower (P < 0.001) compared to 
female patients (76 (range 66–82) years) (Tab. 5).
Large-artery atherosclerosis and cardioembolisms were 
significantly more often recognised in RIS than in first-ever 
ischaemic stroke (FIS) (consecutively, 38.2% vs 36.0%, and 21% 
vs 18.1%; p < 0.001). On the other hand, lacunar stroke was less 
279www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Beata Łabuz-Roszak et al., Recurrent stroke in Silesian Province
Table 1. Number of acute (first and recurrent) stroke-related hospitalisations in the Silesian Province between 2009 and 2015 (no data on sex in 487 patients 
in 2012)
Year Number of hospitalisations due  
to acute stroke  
N (%)
Number of hospitalisations  
in women 
N (%)
Number of hospitalisations  
in men 
N (%)
2009 All 11,083 (100) 5,697 (100) 5,386 (100)
FS 7,987 (72.1) 4,061 (71.3) 3,926 (72.9)
RS 2,559 (23.1) 1,338 (23.5) 1,221 (22.7)
ND 537 (4.9) 298 (5.2) 239 (4.4)
2010 All 11,751 (100) 6,126 (100) 5,625 (100)
FS 8,598 (73.2) 4,465 (72.9) 4,133 (73.5)
RS 2,681 (22.8) 1,391 (22.7) 1,290 (22.9)
ND 472 (4) 270 (4.4) 202 (3.6)
2011 All 11,921 (100) 6,139 (100) 5,782 (100)
FS 8,618 (72.3) 4,409 (71.8) 4,209 (72.8)
RS 2,789 (23.4) 1,443 (23.5) 1,346 (23.3)
ND 514 (4.3) 287 (4.7) 227 (3.9)
2012 All 11,912 (100) 5,905 (100) 5,520 (100)
FS 8,690 (72.9) 4,282 (72.5) 4,052 (73.4)
RS 2,725 (22.9) 1,350 (22.9) 1,256 (22.8)
ND 497 (4.2) 273 (4.6) 212 (3.8)
2013 All 11,926 (100) 6,202 (100) 5,724 (100)
FS 8,605 (72.2) 4,486 (72.3) 4,119 (72.0)
RS 2,668 (22.4) 1,368 (22.1) 1,300 (22.7)
ND 653 (5.5) 348 (5.6) 305 (5.3)
2014 All 11,505 (100) 5,956 (100) 5,549 (100)
FS 8,143 (70.8) 4,261 (71.5) 3,882 (70.0)
RS 2,413 (21.0) 1,210 (20.3) 1,203 (21.7)
ND 949 (8.3) 485 (8.1) 464 (8.4)
2015 All 11,095 (100) 5,671 (100) 5,424 (100)
FS 7,726 (69.6) 3,924 (69.2) 3,802 (70.1)
RS 2,228 (20.1) 1,129 (19.9) 1,099 (20.3)
ND 1,141 (10.3) 618 (10.9) 523 (9.6)
All All 81,193 (100) 39,010 (100) 41,696 (100)
FS 58,367 (71.9) 28,123 (72.1) 29,888 (71.7)
RS 18,063 (22.2) 8,715 (22.3) 9,229 (22.1)
ND 4,763 (5.9) 2,172 (5.6) 2,579 (6.2)
Pa for trend < 0.001 < 0.001 0.173
All – all stroke types (I60-I64); FS – first-ever-stroke; RS – recurrent stroke; ND – no data on type of stroke; a – Cochran–Armitage test for trend with Holm-Bonferroni correction
often diagnosed in RIS than in FIS (8.8% vs 10.0%; p < 0.001). 
The aetiology of stroke was undetermined in 30.4% of subjects 
of RIS compared to 34.1% of subjects of FIS (p < 0.001) (Tab. 6). 
The clinical manifestation of stroke was significantly more 
expressed in RIS than in FIS (p < 0.001) (Tab. 7).
During the analysed period, the in-hospital mortality rate 
for RS was 18.4%, and it was significantly higher compared to 
FS (17.2%) (p < 0.001). The same observation was done for RIS 
vs FIS (16.2% vs 13.9%; p < 0.001), and for RHS vs first-ever 
haemorrhagic stroke (FHS) (39.8% vs 36%; p = 0.004). The 
same trend was seen in women and in men (Tab. 8–10).
The median hospitalisation time was 14 (range 5–24) days 
for RHS, and 11 (range 9–15) days for RIS (Tab. 11). 77.2% of 
patients with FS and 78.9% of patients with RS were admit-
ted to hospital on the day when stroke symptoms appeared 
(p < 0.001).
The rtPA therapy was applied to 2,598 patients with FIS 
(5.3%) and to 525 patients with RIS (3.2%) treated in hospitals 
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of the Silesian Province between 2009 and 2015 (p < 0.001) 
(Tab. 2). The percentage changed between 2009 and 2015 from 
1.3% (FIS) and 0.7% (RIS) to 10.3% (FIS) and 6.7% (RIS).
The overall in-hospital mortality in patients with FIS trea-
ted with rtPA (n = 396; 15.2%) was not statistically significantly 
higher compared to the in-hospital mortality of patients with 
FIS untreated with rtPA (n = 6,489; 13.9%) (P = 0.142). Also, 
the overall in-hospital mortality in patients with RIS treated 
with rtPA (n = 87; 16.6%) was not statistically significantly 
higher compared to the in-hospital mortality of patients with 
RIS untreated with rtPA (n = 2,548; 16.2%) (P = 0.885). No 
difference was found between the in-hospital mortality of FIS 
patients and the in-hospital mortality of RIS patients treated 
with rtPA (p = 0.885). Gender did not influence the in-hospital 
mortality in patients treated with rtPA (Tab. 12–13). 
The in-hospital mortality in patients either with RIS or 
FIS was significantly higher in cardiogenic stroke compared 
to atherogenic stroke (Tab. 14–15).
The in-hospital mortality in patients either with FIS or 
RIS treated with rtPA was not associated with aetiology of 
stroke (Tab. 16–17).
Data obtained from the stroke questionnaires allowed us 
to determine the secondary stroke prevention therapy; 81.7% 
of RIS patients and 84.3% of FIS patients (p < 0.001) were 
administered antiplatelet drugs, 26.2% of RIS subjects and 
23% of FIS subjects – oral anticoagulants (p < 0.001), and 
subsequently, 84.4% and 79.9% - antihypertensive drugs (p < 
0.001) (Tab. 18). Furthermore, 3.4% of patients with FIS and 
3.1% of patients with RIS were referred for vascular interven-
tion due to artery stenosis.
In patients with cardioembolic stroke aetiology, 37.5% of 
subjects with FIS and 40.6% of subjects with RIS were admi-
nistered anticoagulants. The percentage of patients with RIS 
Table 2. Rt-PA therapy in patients hospitalised due to first-ever and recurrent ischaemic stroke (I63) in the Silesian Province between 2009 and 2015
Year Number of all  
hospitalisations 
due to FIs 
N
Number of all  
hospitalisations 
due to rIs 
N
Number of all  
patients treated 
with rt-PAa 
/percentage of 
treated patients 
to all patients with 
I63 diagnosis /
Number of  
patients with FIs 
treated with rt-PA 
/percentage of 
treated patients 
to all patients with 
FIs diagnosis /
Number of  
patients with rIs 
treated with rt-PA 
/percentage of 
treated patients 
to all patients with 
rIs diagnosis /
Pb 
FIs vs rIs treated 
with rt-PA
2009 6,584 2,277 107 /1.2%/ 88 (1.3%) 17 (0.7%) 0.025
2010 7,298 2,397 196 /1.9%/ 164 (2.2%) 27 (1.1%) 0.002
2011 7,314 2,517 296 /2.9%/ 242 (3.3%) 50 (2%) 0.002
2012 7,339 2,469 453 /4.4%/ 366 (5%) 82 (3.3%) 0.002
2013 7,353 2,422 537 /5.2%/ 439 (6%) 84 (3.5%) < 0.001
2014 6,937 2,169 806 /8.2%/ 620 (8.9%) 131 (6%) < 0.001
2015 6,600 2,005 887 (9.3%) 679 (10.3%) 134 (6.7%) < 0.001
Pa for trend - - < 0.001 < 0.001 < 0.001 -
All 49,425 16,256 3,282 (4.7%) 2,598 (5.3%) 525 (3.2%) < 0.001
a – Cochran–Armitage test for trend with Holm-Bonferroni correction 
b – Chi2 test with Holm-Bonferroni correction
and cardioembolic stroke treated with anticoagulants gradually 
increased over the subsequent years (p = 0.033) while a negative 
trend was observed for antiplatelet drugs (p = 0.004) (Tab. 19). 
Discussion
As we described in our previous paper, the number of 
hospitalisations due to stroke and the incidence of first-ever-
-stroke in the Silesian Province were high (from 169/100,000 in 
2009 to 187/100,000 in 2015), and seemed to be more akin to 
Eastern rather than to Western European countries [15, 18, 
19]. This suggests that primary prevention of stroke may be 
imperfectly implemented in our country, and that the aware-
ness of cerebrovascular risk factors is insufficient. 
On the other hand, the number of recurrent strokes is the 
indictor of the efficiency of secondary prevention. Our study 
shows that hospitalisations due to recurrent stroke constituted 
a little more than one fifth of all hospitalisations due to acute 
stroke. The recurrence is higher in IS than in HS. The selected 
epidemiological studies show that the risk of recurrence after 
a first-ever stroke reaches 4% at 1 month, 13% at 1 year, and 
almost 40% at 10 years [20–24]. Readmission to hospital has 
a negative effect on the quality of a patient’s life and increases 
socioeconomic costs [25].
We have found that the number of RS has significantly 
decreased during the last decade (RS constituted 23.1% 
of all stroke hospitalisations in 2009 but 20.1% in 2015; 
p < 0.001). In the Warsaw Stroke Registry (conducted 
in 1991–1992), recurrent strokes constituted 27% of all 
acute stroke events observed during the study [2, 3]. In 
our study, a  decreasing number concerned RIS, but not 
RHS. This is consistent with other studies [20, 26]. The 
decreasing number of recurrent strokes could be associated 
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table 3. Number of acute (first and recurrent) ischaemic stroke–related hospitalisations in the Silesian Province between 2009 and 2015 
Year Number of hospitalisations due  
to acute stroke  
N (%)
Number of hospitalisations  
in women 
N (%)
Number of hospitalisations  
in men 
N (%)
2009 All 9,275 (100) 4,789 (100) 4,486 (100)
FIS 6,584 (71.0) 3,346 (69.9) 3,238 (72.2)
RIS 2,277 (24.5) 1,208 (25.2) 1,069 (23.8)
ND 414 (4.5) 235 (4.9) 179 (4.0)
2010 All 10,058 (100) 5,284 (100) 4,774 (100)
FIS 7,298 (72.6) 3,816 (72.2) 3,482 (72.9)
RIS 2,397 (23.8) 1,262 (23.9) 1,135 (23.8)
ND 363 (3.6) 206 (3.9) 157 (3.3)
2011 All 10,223 (100) 5,303 (100) 4,920 (100)
FIS 7,314 (71.5) 3,764 (71.0) 3,550 (72.2)
RIS 2,517 (24.6) 1,318 (24.9) 1,199 (24.4)
ND 392 (3.8) 221 (4.2) 171 (3.5)
2012 All 10,187 (100) 5,078 (100) 4,693 (100)
FIS 7,339 (72.0) 3,632 (71.5) 3,407 (72.6)
RIS 2,469 (24.2) 1,232 (24.3) 1,129 (24.1)
ND 379 (3.7) 214 (4.2) 157 (3.4)
2013 All 10,289 (100) 5,393 (100) 4,896 (100)
FIS 7,353 (71.5) 3,853 (71.4) 3,500 (71.5)
RIS 2,422 (23.5) 1,258 (23.3) 1,164 (23.8)
ND 514 (5) 282 (5.2) 232 (4.7)
2014 All 9,850 (100) 5,143 (100) 4,707 (100)
FIS 6,937 (70.4) 3,653 (71.0) 3,284 (69.8)
RIS 2,169 (22.0) 1,104 (21.5) 1,065 (22.6)
ND 744 (7.6) 386 (7.5) 358 (7.6)
2015 All 9,521 (100) 4,890 (100) 4,631 (100)
FIS 6,600 (69.3) 3,368 (68.9) 3,232 (69.8)
RIS 2,005 (21.1) 1,012 (20.7) 993 (21.4)
ND 916 (9.6) 5,10 (10.4) 406 (8.8)
All All 69,403 (100) 35,880 (100) 33,107 (100)
FIS 49,425 (71.2) 25,432 (70.9) 23,693 (71.6)
RIS 16,256 (23.4) 8,394 (23.4) 7,754 (23.4)
ND 3,722 (5.4) 2,054 (5.7) 1,660 (5.0)
Pa for 
trend
< 0.001 < 0.001 0.209
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63); ND – no data; 
a – Cochran–Armitage test for trend with Holm–Bonferroni correction
with a  better stroke care network and improvements in 
secondary stroke prevention.
This is also consistent with the observation that the num-
ber of stroke survivals with atrial fibrillation on anticoagulants 
increased from 40% in 2009 to 44% in 2015.
As regards the aetiology of RIS, this was undetermined 
in less than one third of patients (for comparison, in 1991–
1992 this figure was more than half) [2, 3]. Such a decrease in 
unknown aetiology might be the result of a greater availability 
of diagnostic methods (such as ultrasonography, magnetic 
resonance, angiography, and broader cardiologic diagnostic 
possibilities). It is worth emphasising that undetermined RIS 
was rarer than undetermined FIS (30% vs 34%). The most 
common reason for RIS was large-artery atherosclerosis. Car-
dioembolisms were responsible for 21% of RIS (18% in FIS). 
In our study we could not establish the recurrence rates 
for different subtypes of ischaemic stroke because the fin-
dings were anonymous. From the literature, we can see that 
282
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 4
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
table 4. Number of acute (first and recurrent) haemorrhagic stroke–related hospitalisations in the Silesian Province between 2009 and 2015 
Year Number of hospitalisations due  
to acute stroke 
N (%)
Number of hospitalisations  
in women 
N (%)
Number of hospitalisations  
in men 
N (%)
2009 All 1,604 (100) 798 (100) 806 (100)
FHS 1,251 (78.0) 629 (78.8) 622 (77.2)
RHS 246 (15.3) 115 (14.4) 131 (16.3)
ND 107 (6.7) 54 (6.8) 53 (6.6)
2010 All 1,578 (100) 783 (100) 795 (100)
FHS 1,219 (77.3) 608 (77.7) 611 (76.9)
RHS 255 (16.2) 113 (14.4) 142 (17.9)
ND 104 (6.6) 62 (7.9) 42 (5.3)
2011 All 1,562 (100) 747 (100) 815 (100)
FHS 1,211 (77.5) 583 (78.1) 628 (77.1)
RHS 245 (15.7) 108 (14.5) 137 (16.8)
ND 106 (6.8) 56 (7.5) 50 (6.1)
2012 All 1,596 (100) 761 (100) 771 (100)
FHS 1,260 (79.0) 604 (79.4) 605 (78.5)
RHS 233 (14.6) 104 (13.7) 119 (15.4)
Na’s 103 (6.5) 53 (7.0) 47 (6.1)
2013 All 1,518 (100) 740 (100) 778 (100)
FHS 1,169 (77.0) 584 (78.9) 585 (75.2)
RHS 220 (14.5) 97 (13.1) 123 (15.8)
Na’s 129 (8.5) 59 (8.0) 70 (9.0)
2014 All 1,531 (100) 740 (100) 791 (100)
FHS 1,125 (73.5) 557 (75.3) 568 (71.8)
RHS 219 (14.3) 94 (12.7) 125 (15.8)
Na’s 187 (12.2) 89 (12.0) 98 (12.4)
2015 All 1,439 (100) 711 (100) 728 (100)
FHS 1,038 (72.1) 511 (71.9) 527 (72.4)
RHS 201 (14.0) 105 (14.8) 96 (13.2)
Na’s 200 (13.9) 95 (13.4) 105 (14.4)
All All 10,828 (100) 5,280 (100) 5,484 (100)
FHS 8,273 (76.4) 4,076 (77.2) 4,146 (75.6)
RHS 1,619 (15.0) 736 (13.9) 873 (15.9)
Na’s 936 (8.6) 468 (8.9) 465 (8.5)
Pa for 
trend
0.476 0.957 0.305
FHS – first–ever haemorrhagic stroke (I60–I62); RHS – recurrent haemorrhagic stroke (I60–I62); ND – no data; a – Cochran–Armitage test for trend with Holm–Bonferroni correction
the 3-month recurrence rates are higher for stroke caused by 
large artery atherosclerosis (14.3%) than for cardioembolic 
stroke (7.7%), lacunar stroke (2%) and ischaemic stroke due 
to undetermined causes (5.6%) [27]. A 23-year longitudinal 
population-based study showed that the implementation of 
a stroke care network and good primary prevention are defined 
areas associated with a decrease in the number of recurrent 
strokes [26].
The clinical symptoms were significantly more expressed 
in RIS than in FIS. Similarly to other authors, we found that 
hemiparesis/hemiplegia and speech disorders were the most 
common presenting symptoms [28]. 
The median length of hospital stay was 11 (range 9–15) 
days for RIS and 14 (range 5–24) days for RHS, both shorter 
than previously described [29]. Hospitalisation time was simi-
lar for RIS and FIS, but longer for RHS than for FHS.
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table 5. Median (Q1–Q3) age of patients with stroke in the analysed period
Year Fs rs Pa FIs rIs Pa FHs rHs Pa
2009 72 (62–80) 74 (66–81) < 0.001 73 (63–80) 75 (66–81) < 0.001 70 (56–78) 73 (63–80) < 0.001
2010 72 (62–80) 74 (65–81) < 0.001 73 (62–80) 74 (65–81) < 0.001 68 (56–79) 72 (62–79) 0.009
2011 73 (62–81) 74 (65–81) < 0.001 73 (63–81) 74 (65–81) < 0.001 68 (57–79) 71 (62–80) 0.012
2012 73 (62–81) 74 (65–81) < 0.001 73 (63–81) 75 (65–81) < 0.001 67 (56–78) 70 (61–78) 0.004
2013 73 (63–81) 74 (65.5–81) < 0.001 73 (63–81) 74 (66–82) < 0.001 70 (59–79) 72 (61–79) 0.139
2014 73 (63–81) 75 (66–82) < 0.001 73 (64–82) 75 (66–82) < 0.001 70 (59–79) 73 (64–80) 0.003
2015 73 (63–81) 75 (66–82) < 0.001 73 (64–81) 75 (67–83) < 0.001 70 (59–80) 74 (65–80) 0.001
Pb for trend < 0.001 < 0.001 – < 0.001 < 0.001 – 0.001 0.206 –
All 73 (62–81) 74 (66–81) < 0.001 73 (63–81) 75 (66–81) < 0.001 69 (57–79) 72 (62–80) < 0.001
a – U Mann–Whitney test;
b – Jonckheere–Terpstra test for trend with Holm–Bonferroni correction;
FS – first–ever stroke; RS – recurrent stroke;
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63);
FHS – first–ever haemorrhagic stroke (I60–I62); RHS – recurrent haemorrhagic stroke (I60–I62)
table 6. Aetiology of ischaemic stroke in the Silesian Province between 2009 and 2015, according to the TOAST classification 
Year Aetiology of ischaemic stroke Pa
Large–artery at-
herosclerosis
cardio– 
–embolism
small–vessel  
occlusion (lacune)
Other determined 
aetiology
Undetermined 
aetiology
2009 FIS 2,502 (38.0%) 1,026 (15.6%) 683 (10.4%) 141 (2.1%) 2,232 (33.9%) < 0.001
RIS 875 (38.4%) 455 (20.0%) 215 (9.4%) 34 (1.5%) 698 (30.7%)
2010 FIS 2,672 (36.6%) 1,093 (15.0%) 642 (8.8%) 111 (1.5%) 2,780 (38.1%) < 0.001
RIS 912 (38.1%) 463 (19.3%) 177 (7.4%) 35 (1.5%) 810 (33.8%)
2011 FIS 2,579 (35.3%) 1,348 (18.4%) 699 (9.6%) 110 (1.5%) 2,578 (35.3%) < 0.001
RIS 988 (39.3%) 512 (20.3%) 230 (9.1%) 24 (1.0%) 763 (30.3%)
2012 FIS 2,720 (37.1%) 1,473 (20.1%) 713 (9.7%) 135 (1.8%) 2,298 (31.3%) 0.004
RIS 943 (38.2%) 555 (22.5%) 187 (7.6%) 49 (2.0%) 735 (29.8%)
2013 FIS 2,540 (34.5%) 1,395 (19.0%) 778 (10.6%) 126 (1.7%) 2,514 (34.2%) < 0.001
RIS 919 (37.9%) 539 (22.3%) 220 (9.1%) 33 (1.4%) 711 (29.4%)
2014 FIS 2,407 (34.7%) 1,312 (18.9%) 738 (10.6%) 166 (2.4%) 2,314 (33.4%) 0.001
RIS 824 (38.0%) 454 (20.9%) 211 (9.7%) 35 (1.6%) 645 (29.7%)
2015 FIS 2,388 (36.2%) 1,276 (19.3%) 675 (10.2%) 125 (1.9%) 2,136 (32.4%) 0.010
RIS 751 (37.5%) 442 (22.0%) 191 (9.5%) 42 (2.1%) 579 (28.9%)
Pb for trend 0.289 < 0.001 0.626 0.751 0.082 –
Total FIS 17,808 (36.0%) 8,923 (18.1%) 4,928 (10.0%) 914 (1.9%) 16,852 (34.1%) < 0.001
RIS 6,212 (38.2%) 3,420 (21.0%) 1,431 (8.8%) 252 (1.6%) 4,941 (30.4%)
a – Chi2 test with Holm–Bonferroni correction
b – Cochran–Armitage test for trend with Holm–Bonferroni correction
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63)
table 7. Clinical symptoms of acute stroke in the Silesian Province between 2009 and 2015
ALL strOKEs 
(I60–I64)
Fs 
(I60–I64)
rs 
(I60–I64)
P
Consciousness disorders 26,302 (34.4%) 19,301 (33.1%) 7,001 (38.8%) < 0.001
Hemiparesis/ hemiplegia 61,984 (81.1%) 46,670 (80.0%) 15,314 (84.8%) < 0.001
Speech disorders 45,117 (59.0%) 33,221 (56.9%) 11,896 (65.9%) < 0.001
Sensation disorders 25,026 (32.7%) 18,735 (32.1%) 6,291 (34.8%) < 0.001
Posterior circle syndrome 17,180 (22.5%) 12,943 (22.2%) 4,237 (23.5%) < 0.001
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table 8. In–hospital mortality in acute first–ever and recurrent stroke in the Silesian Province between 2009 and 2015. Data presented as the number and 
percentage of deaths, n (%) 
Year Overall ho-
spital morta-
lity in Fs
Overall ho-
spital morta-
lity in rs
P 
Fs vs 
rs
Mortality  
in FIs
Mortality 
 in rIs
P 
FIs vs 
rIs
Mortality  
in FHs
Mortality 
 in rHs
P 
FHs vs 
rHs
2009 1,440 (18.0%) 510 (19.9%) 0.187 954 (14.5%) 396 (17.4%) 0.005 410 (32.8%) 99 (40.2%) 0.166
2010 1,460 (17.0%) 519 (19.4%) 0.033 1,010 (13.8%) 405 (16.9%) 0.002 435 (35.7%) 110 (43.1%) 0.166
2011 1,523 (17.7%) 521 (18.7%) 0.696 1,074 (14.7%) 420 (16.7%) 0.047 422 (34.8%) 93 (38.0%) 1.000
2012 1,468 (16.9%) 491 (18.0%) 0.696 1,004 (13.7%) 395 (16.0%) 0.018 454 (36.0%) 94 (40.3%) 1.000
2013 1,459 (17.0%) 459 (17.2%) 1.000 994 (13.5%) 363 (15.0%) 0.139 452 (38.7%) 87 (39.5%) 1.000
2014 1,342 (16.5%) 432 (17.9%) 0.504 910 (13.1%) 338 (15.6%) 0.018 419 (37.2%) 91 (41.6%) 1.000
2015 1,340 (17.3%) 394 (17.7%) 1.000 939 (14.2%) 318 (15.9%) 0.139 384 (37.0%) 70 (34.8%) 1.000
Pb for trend 0.261 0.035 – 0.261 0.105 – 0.035 0.0321 –
All 10,032 (17.2%) 3,326 (18.4%) < 0.001 6,885 (13.9%) 2,635 (16.2%) < 0.001 2,976 (36.0%) 644 (39.8%) 0.004
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63);
FHS – first–ever haemorrhagic stroke (I60–I62); RHS – recurrent haemorrhagic stroke (I60–I62)
Data presented as N (%)
a – Chi2 test with Holm–Bonferroni correction
b – Cochran–Armitage test for trend with Holm–Bonferroni correction (level of significance for trend in in–hospital mortality between 2009 and 2015)
table 9. In–hospital mortality in acute first–ever and recurrent stroke in women in the Silesian Province between 2009 and 2015. Data presented as the 
number and percentage of deaths, n (%) 
Year Overall female 
hospital mor-
tality in Fs
Overall female 
hospital mor-
tality in rs
P 
Fs vs 
rs
Mortality  
in FIs
Mortality  
in rIs
P 
FIs vs 
rIs
Mortality  
in FHs
Mortality  
in rHs
P 
FHs vs 
rHs
2009 804 (19.8%) 271 (20.3%) 1.000 539 (16.1%) 226 (18.7%) 0.172 220 (35.0%) 42 (36.5%) 1.000
2010 812 (18.2%) 283 (20.3%) 0.499 590 (15.5%) 229 (18.1%) 0.172 215 (35.4%) 52 (46.0%) 0.219
2011 849 (19.3%) 294 (20.4%) 1.000 607 (16.1%) 248 (18.8%) 0.172 219 (37.6%) 41 (38.0%) 1.000
2012 782 (18.3%) 256 (19.0%) 1.000 558 (15.4%) 222 (18.0%) 0.172 218 (36.1%) 34 (32.7%) 1.000
2013 822 (18.3%) 253 (18.5%) 1.000 589 (15.3%) 201 (16.0%) 1.000 226 (38.7%) 47 (48.5%) 0.36
2014 757 (17.8%) 227 (18.8%) 1.000 543 (14.9%) 181 (16.4%) 0.644 204 (36.6%) 44 (46.8%) 0.36
2015 760 (19.4%) 212 (18.8%) 1.000 549 (16.3%) 169 (16.7%) 1.000 202 (39.5%) 40 (38.1%) 1.000
Pb for trend 0.977 0.492 – 1.000 0.202 – 0.492 1.000 –
All 5,586 (18.7%) 1,796 (19.5%) 0.098 3,975 (15.6%) 1,476 (17.6%) < 0.001 1,504 (36.9%) 300 (40.8%) 0.046
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63);
FHS – first–ever haemorrhagic stroke (I60–I62); RHS – recurrent haemorrhagic stroke (I60–I62)
Data presented as N (%)
a – Chi2 test with Holm–Bonferroni correction
b – Cochran–Armitage test for trend with Holm–Bonferroni correction (level of significance for trend in in–hospital mortality between 2009 and 2015)
table 10. In–hospital mortality in acute first–ever and reccurent stroke in men in the Silesian Province between 2009 and 2015. Data presented as the num-
ber and percentage of deaths, n (%) 
Year Overall male 
hospital mor-
tality in Fs
Overall male 
hospital mor-
tality in rs
Pa 
Fs vs 
rs
Mortality  
in FIs
Mortality 
in rIs
P 
FIs vs 
rIs
Mortality  
in FHs
Mortality in 
rHs
P 
FHs vs 
rHs
2009 636 (16.2%) 239 (19.6%) 0.043 415 (12.8%) 170 (15.9%) 0.053 190 (30.5%) 57 (43.5%) 0.029
2010 648 (15.7%) 236 (18.3%) 0.158 420 (12.1%) 176 (15.5%) 0.016 220 (36.0%) 58 (40.8%) 1.000
2011 674 (16.0%) 227 (16.9%) 0.921 467 (13.2%) 172 (14.3%) 0.296 203 (32.3%) 52 (38.0%) 1.000
2012 629 (15.5%) 217 (17.3%) 0.552 410 (12.0%) 159 (14.1%) 0.143 216 (35.7%) 56 (47.1%) 0.116
2013 637 (15.5%) 206 (15.8%) 0.921 405 (11.6%) 162 (13.9%) 0.102 226 (38.6%) 40 (32.5%) 1.000
2014 585 (15.1%) 205 (17.0%) 0.496 367 (11.2%) 157 (14.7%) 0.013 215 (37.9%) 47 (37.6%) 1.000
2015 580 (15.3%) 182 (16.6%) 0.879 390 (12.1%) 149 (15.0%) 0.061 182 (34.5%) 30 (31.3%) 1.000
Pb for trend 0.267 0.165 – 0.198 0.400 – 0.165 0.198 –
All 4,389 (15.6%) 1,512 (17.4%) < 0.001 2,874 (12.1%) 1,145 (14.8%) < 0.001 1,452 (35.0%) 340 (39.0%) 0.028
FIS – first–ever ischaemic stroke (I63); RIS – recurrent ischaemic stroke (I63);
FHS – first–ever haemorrhagic stroke (I60–I62); RHS – recurrent haemorrhagic stroke (I60–I62)
Data presented as N (%)
a – Chi2 test with Holm–Bonferroni correction
b – Cochran–Armitage test for trend with Holm–Bonferroni correction (level of significance for trend in in–hospital mortality between 2009 and 2015)
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table 11. Hospitalisation time of patients with first–ever and recurrent stroke in the Silesian Province between 2009 and 2015. Data presented as median 
(Q1–Q3) in days
Year Fs rs pa FIs rIs pa FHs rHs pa
2009 11 (9–17) 11 (9–17) 0.463 11 (9–16) 11 (9–16) 0.692 13 (3–25) 14 (6–27) 0.047
2010 11 (9–17) 11 (9–16) 0.347 11 (9–16) 11 (9–16) 0.564 14 (3–25) 13 (4–22) 0.453
2011 11 (9–16) 11 (9–17) 0.161 11 (9–15) 11 (9–16) 0.374 13 (3–24) 15 (5–24) 0.134
2012 11 (9–16) 11 (9–15) 0.934 10 (9–15) 11 (9–15) 0.935 12 (3–23) 12 (5–23) 0.366
2013 11 (9–15) 11 (9–15) 0.439 10 (9–15) 11 (9–15) 0.482 13 (3–23) 13 (4–24) 0.197
2014 11 (9–16) 11 (9–16) 0.112 11 (9–15) 11 (9–15) 0.255 14 (4–24) 15 (8–24) 0.073
2015 10 (9–15) 11 (9–15) 0.252 10 (9–14) 10 (9–15) 0.724 12 (3–22) 15 (5–22) 0.151
Pb < 0.001 0.116 – < 0.001 0.015 – 0.946 0.946 –
All 11 (9–16) 11 (9–16) 0.073 11 (9–15) 11 (9–15) 0.437 13 (3–24) 14 (5–24) 0.002
a – U Mann–Whitney test
b – Jonckheere–Terpstra test for trend with Holm–Bonferroni correction
table 12. In–hospital mortality in patients treated with intravenous thrombolytic therapy (rt–PA) compared to in–hospital mortality in patients untreated 
with rt–PA in the Silesian Province between 2009 and 2015 
Year Mortality in 
FIs treated 
with rt–PA
Mortality in 
FIs untreated 
with rt–PA
P 
treated vs 
untreated FIs
Mortality in 
rIs treated 
with rt–PA
Mortality in 
rIs untreated 
with rt–PA
P 
treated vs 
untreated rIs
P 
treated FIs vs 
treated rIs
2009 21 (23.9%) 933 (14.4%) 0.071 3 (17.6%) 393 (17.4%) 1.000 1.000
2010 23 (14.0%) 987 (13.8%) 1.000 4 (14.8%) 401 (16.9%) 1.000 1.000
2011 33 (13.6%) 1,041 (14.7%) 1.000 7 (14.0%) 413 (16.7%) 1.000 1.000
2012 53 (14.5%) 951 (13.6%) 1.000 13 (15.9%) 382 (16.0%) 1.000 1.000
2013 56 (12.8%) 938 (13.6%) 1.000 12 (14.3%) 351 (15.0%) 1.000 1.000
2014 104 (16.8%) 806 (12.8%) 0.033 21 (16.0%) 317 (15.6%) 1.000 1.000
2015 106 (15.6%) 833 (14.1%) 1.000 27 (20.1%) 291 (15.6%) 1.000 1.000
Pa for trend 0.982 0.173 – 0.739 0.060 – –
All 396 (15.2%) 6,489 (13.9%) 0.142 87 (16.6%) 2,548 (16.2%) 0.885 0.885
a – Chi2 test with Holm–Bonferroni correction
table 13. Comparison of in–hospital mortality in men treated with intravenous thrombolytic therapy (rt–PA) to in–hospital mortality in women treated with 
rt–PA in the Silesian Province between 2009 and 2015
Year Mortality in men in 
FIs treated with rt–PA
Mortality in women 
in FIs treated with 
rt–PA
P 
F vs M
Mortality in men 
in rIs treated with 
rt–PA
Mortality in women 
in rIs treated with 
rt–PA
P 
F vs M
2009 9 (22.0%) 12 (25.5%) 1.000 3 (30.0%) 0 (0%) 0.772
2010 13 (14.3%) 10 (13.7%) 1.000 1 (10.0%) 3 (17.6%) 1.000
2011 22 (15.8%) 11 (10.7%) 1.000 3 (12.5%) 4 (15.4%) 1.000
2012 26 (13.9%) 24 (15.2%) 1.000 8 (17.8%) 5 (16.1%) 1.000
2013 24 (10.5%) 32 (15.2%) 0.949 4 (9.8%) 8 (18.6%) 1.000
2014 55 (16.9%) 49 (16.6%) 1.000 9 (13.6%) 12 (18.5%) 1.000
2015 52 (15.3%) 54 (15.9%) 1.000 18 (24.7%) 9 (14.8%) 0.928
Pa for trend 1.000 1.000 – 1.000 1.000 –
All 201 (14.9%) 192 (15.7%) 0.570 46 (17.1%) 41 (16.4%) 0.831
a – Chi2 test with Holm–Bonferroni correction
286
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 4
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
table 14. In–hospital mortality (n, %) in association with the aetiology of FIS in the Silesian Province between 2009 and 2015 
Year Atiology of ischaemic stroke Pa
Large–artery  
atherosclerosis
cardio–embolism small–vessel  
occlusion (lacune)
Other determined 
aetiology
Undetermined 
aetiology
2009 344 (13.8%) 196 (19.1%) 15 (2.2%) 18 (12.8%) 381 (17.1%) < 0.001
2010 359 (13.4%) 194 (17.8%) 22 (3.4%) 13 (11.7%) 422 (15.2%) < 0.001
2011 327 (12.7%) 299 (22.2%) 32 (4.6%) 15 (13.6%) 401 (15.6%) < 0.001
2012 375 (13.8%) 262 (17.8%) 31 (4.4%) 13 (9.6%) 323 (14.1%) < 0.001
2013 338 (13.3%) 262 (18.8%) 47 (6%) 6 (4.8%) 341 (13.6%) < 0.001
2014 287 (11.9%) 233 (17.8%) 36 (4.9%) 14 (8.4%) 340 (14.7%) < 0.001
2015 330 (13.8%) 226 (17.7%) 48 (7.1%) 20 (16.0%) 315 (14.8%) < 0.001
Pb for trend 1.000 0.468 < 0.001 1.000 0.045 –
Total 2.360 (13.3%) 1.672 (18.7%) 231 (4.7%) 99 (10.8%) 2.523 (15%) < 0.001
a – Chi2 test with Holm–Bonferroni correction 
b – Cochran–Armitage test for trend with Holm–Bonferroni correction
table 15. In–hospital mortality (n, %) in association with the aetiology of RIS in the Silesian Province between 2009 and 2015
Year Aetiology of ischaemic stroke Pa
Large–artery  
atherosclerosis
cardio–embolism small–vessel  
occlusion (lacune)
Other determined 
aetiology
Undetermined 
aetiology
2009 159 (18.2%) 88 (19.3%) 13 (6.1%) 2 (5.9%) 134 (19.2%) < 0.001
2010 148 (16.2%) 100 (21.6%) 15 (8.5%) 4 (11.4%) 138 (17.0%) 0.004
2011 159 (16.1%) 112 (21.9%) 16 (7.0%) 3 (12.5%) 130 (17.0%) < 0.001
2012 145 (15.4%) 114 (20.5%) 12 (6.4%) 7 (14.3%) 117 (15.9%) 0.001
2013 131 (14.3%) 98 (18.2%) 15 (6.8%) 3 (9.1%) 116 (16.3%) 0.004
2014 148 (18.0%) 85 (18.7%) 15 (7.1%) 7 (20.0%) 83 (12.9%) 0.001
2015 119 (15.9%) 83 (18.8%) 18 (9.4%) 9 (21.4%) 89 (15.4%) 0.043
Pb for trend 0.795 0.720 0.795 0.168 0.031 –
Total 1009 (16.2%) 680 (19.9%) 104 (7.3%) 35 (13.9%) 807 (16.3%) < 0.001
a – Chi2 test with Holm–Bonferroni correction 
b – Cochran–Armitage test for trend with Holm–Bonferroni correction
table 16. In–hospital mortality in patients treated with rt–PA (n, %) in association with the aetiology of first–ever ischaemic stroke (I63; n=49,452) in the 
Silesian Province between 2009 and 2015
Year Aetiology of ischaemic stroke Pa
Large–artery  
atherosclerosis
cardio–embolism small–vessel  
occlusion (lacune)
Other determined 
aetiology
Undetermined 
aetiology
2009 11 (36.7%) 2 (11.1%) 0 (0%) 0 (0%) 8 (22.2%) 0.657
2010 8 (11.6%) 5 (15.2%) 0 (0%) 0 (0%) 10 (20.4%) 1.000
2011 12 (15.6%) 11 (17.5%) 1 (4.8%) 0 (0%) 9 (11.4%) 1.000
2012 18 (16.5%) 18 (16.2%) 2 (7.7%) 0 (0%) 15 (13.3%) 1.000
2013 15 (11.1%) 18 (13.5%) 2 (7.1%) 0 (0%) 21 (15.1%) 1.000
2014 32 (15.3%) 41 (23.6%) 6 (12.5%) 1 (14.3%) 24 (13.2%) 0.545
2015 32 (13.5%) 26 (14.1%) 4 (8.3%) 2 (28.6%) 42 (20.9%) 0.545
Pb for trend 0.505 1.000 0.681 0.290 1.000 –
Total 128 (14.8%) 121 (16.9%) 15 (8.2%) 3 (9.7%) 129 (16.2%) 0.040
a – Chi2 test with Holm–Bonferroni correction 
b – Cochran–Armitage test for trend with Holm–Bonferroni correction
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table 17. In–hospital mortality in patients treated with rt–PA (n, %) in association with the aetiology of RIS in the Silesian Province between 2009 and 2015
Year Aetiology of ischaemic stroke Pa
Large–artery 
 atherosclerosis
cardio–embolism small–vessel  
occlusion (lacune)
Other determined 
aetiology
Undetermined 
aetiology
2009 1 (14.3%) 1 (50%) 0 (0%) 0 (0%) 1 (14.3%) 1.000
2010 3 (25%) 0 (0%) 0 (0%) 0 (0%) 1 (11.1%) 1.000
2011 3 (15.8%) 2 (12.5%) 0 (0%) 0 (0%) 2 (22.2%) 1.000
2012 6 (19.4%) 3 (17.7%) 0 (0%) 0 (0%) 4 (13.3%) 1.000
2013 5 (13.5%) 5 (25%) 0 (0%) 0 (0%) 2 (8%) 1.000
2014 10 (18.9%) 8 (19.5%) 0 (0%) 1 (50%) 2 (7.1%) 1.000
2015 9 (17.7%) 4 (13.8%) 4 (28.6%) 0 (0%) 10 (26.3%) 1.000
Pb for trend 1.000 1.000 0.419 1.000 1.000 –
Total 37 (17.6%) 23 (17.7%) 4 (13.3%) 1 (11.1%) 22 (15.1%) 0.918
a – Chi2 test with Holm–Bonferroni correction 
b – Cochran–Armitage test for trend with Holm–Bonferroni correction
table 18. Secondary stroke prevention in patients with ischaemic stroke (I63) in the Silesian Province between 2009 and 2015. Data presented as N (%)
Year Oral antiplatelet drugs Oral anticoagulant drugs Antihypertensive drugs Direction for vascular 
intervention due to arte-
ry stenosisb
2009 All 7,303 (78.7%) 2,194 (23.7%) 7,095 (76.5%) 202 (2.2%)
FIS 5,267 (80.0%) 1,511 (22.9%) 4,924 (74.8%) 162 (2.5%)
RIS 1,760 (77.3%) 605 (26.6%) 1,869 (82.1%) 38 (1.7%)
2010 All 8,383 (83.3%) 2,650 (26.3%) 7,939 (78.9%) 350 (3.5%)
FIS 6,177 (84.6%) 1,879 (25.7%) 5,678 (77.8%) 272 (3.7%)
RIS 1,939 (80.9%) 722 (30.1%) 1,994 (83.2%) 71 (3.0%)
2011 All 8,535 (83.5%) 2,608 (25.5%) 8,233 (80.5%) 315 (3.1%)
FIS 6,191 (84.6%) 1,846 (25.2%) 5,862 (80.1%) 230 (3.1%)
RIS 2,054 (81.6%) 694 (27.6%) 2,086 (82.9%) 80 (3.2%)
2012 All 8,655 (85.0%) 2,593 (25.5%) 8,193 (80.4%) 379 (3.7%)
FIS 6,272 (85.5%) 1,805 (24.6%) 5,816 (79.2%) 278 (3.8%)
RIS 2,087 (84.5%) 719 (29.1%) 2,079 (84.2%) 95 (3.8%)
2013 All 8,682 (84.4%) 2,301 (22.4%) 8,331 (81.0%) 344 (3.3%)
FIS 6,245 (84.9%) 1,588 (21.6%) 5,912 (80.4%) 264 (3.6%)
RIS 2,020 (83.4%) 579 (23.9%) 2,031 (83.9%) 68 (2.8%)
2014 All 8,248 (83.7%) 1,965 (19.9%) 8,187 (83.1%) 344 (3.5%)
FIS 5,909 (85.2%) 1,380 (19.9%) 5,820 (83.9%) 249 (3.6%)
RIS 1,794 (82.7%) 480 (22.1%) 1,890 (87.1%) 86 (4.0%)
2015 All 7,830 (82.2%) 1,888 (19.8%) 7,993 (84.0%) 326 (3.4%)
FIS 5,605 (84.9%) 1,335 (20.2%) 5,483 (83.1%) 241 (3.7%)
RIS 1,631 (81.3%) 459 (22.9%) 1,773 (88.4%) 72 (3.6%)
Pa for trend All < 0.001 < 0.001 < 0.001 < 0.001
FIS < 0.001 < 0.001 < 0.001 0.002
RIS < 0.001 < 0.001 < 0.001 < 0.001
ALL All 57,636 (83.0%) 16,199 (23.3%) 55,971 (80.6%) 2,260 (3.2%)
FIS 41,666 (84.3%) 11,344 (23.0%) 39,495 (79.9%) 1,696 (3.4%)
RIS 13,285 (81.7%) 4,258 (26.2%) 13,722 (84.4%) 510 (3.1%)
a – Trend test Cochran–Armitage with Holm–Bonferroni correction 
b – endarterectomy or angioplasty of cervical artery
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table 19. Secondary stroke prevention in patients with ischaemic stroke 
(I63) with cardioembolic aetiology in the Silesian Province between 2009 
and 2015. Data presented as N (%)
Year Oral antiplatelet 
drugs
Oral anticoagulant 
drugs
2009 All 1,081 (68.9%) 589 (37.6%)
FIS 734 (71.5%) 385 (37.5%)
RIS 296 (65.1%) 183 (40.2%)
2010 All 1,203 (74.2%) 604 (37.2%)
FIS 819 (74.9%) 415 (38.0%)
RIS 340 (73.4%) 180 (38.9%)
2011 All 1,402 (72.5%) 697 (36.1%)
FIS 982 (72.8%) 503 (37.3%)
RIS 373 (72.9%) 180 (35.2%)
2012 All 1,545 (73.9%) 766 (36.7%)
FIS 1091 (74.1%) 519 (35.2%)
RIS 404 (72.8%) 234 (42.2%)
2013 All 1,445 (71.4%) 739 (36.5%)
FIS 989 (70.9%) 488 (35.0%)
RIS 389 (72.2%) 211 (39.1%)
2014 All 1,240 (65.7%) 774 (41.0%)
FIS 875 (66.7%) 536 (40.9%)
RIS 284 (62.6%) 207 (45.6%)
2015 All 1,155 (62.5%) 734 (39.7%)
FIS 821 (64.3%) 497 (38.9%)
RIS 271 (61.3%) 195 (44.1%)
Pa for trend All < 0.001 < 0.001
FIS < 0.001 0.253
RIS 0.004 0.033
ALL All 9,071 (69.9%) 4,903 (37.8%)
FIS 6,311 (70.7%) 3,343 (37.5%)
RIS 2357 (68.9%) 1,390 (40.6%)
a – Trend test Cochran–Armitage with Holm–Bonferroni correction
Lekoubou et al. observed that stroke survivors had a 43% 
higher risk of dying after a RS compared to those with FS, be-
cause of unfavourable stroke risk profile [30]. In our study, the 
in-hospital mortality rate was also significantly higher for RS than 
for FS (18.4% vs 17.2%; p < 0.001). The same finding concerned 
RIS vs FIS (16.2% vs 13.9%; p < 0.001), and RHS vs FHS (39.8% 
vs 36%; p = 0.004). This might be also associated with older 
age and more expressed clinical symptoms in patients with RS.
We found that the rtPA therapy was applied to a smaller 
percentage of RIS patients (in 2009 – 0.7%; in 2015 – 6.7%) 
than FIS patients (in 2009 – 1.3%; in 2015 – 10.3%). 
In some Western European countries, the percentage 
of patients with IS treated with rtPA was higher than in the 
Silesian Province e.g. up to 35% in the German state of Hesse 
(2007–2008) [31–33]. Silesia has a dense urban infrastructure 
and the densest hospital network in Poland, so transportation 
seems not to be a problem. In our opinion, the main reason for 
the low percentage of patients treated with rtPA in the Silesian 
Province remains insufficient knowledge and social awareness 
of stroke symptoms and the possibilities of treatment [34, 
35]. Educational programmes should be regularly conducted 
among people using all forms of modern media.
Conclusions
1. Recurrent strokes constituted about one fifth of all stroke 
hospitalisations. However, the recurrence rate of ischaemic 
stroke has systematically decreased over the last decade. 
This is evidence of better secondary stroke prevention. 
2. Large-artery atherosclerosis and cardioembolisms were 
significantly more often recognised in RIS than in FIS, but 
the main reason for RIS was large artery atherosclerosis.
3. The in-hospital mortality rate was significantly higher for 
RS than for FS. 
4. Patients with RIS were almost two times less often treated 
with rtPA than patients with FIS.
5. This was the first such comprehensive analysis of RS in 
the Silesian Province, Poland. This study could help in the 
implementation of appropriate educational programmes, 
and thus help to improve the health status of society.
Limitations of the study
There were a few limitations to this research, as described 
in previous studies [15, 16]. Firstly, in our paper we analysed 
only stroke-related hospitalisations, but in Poland almost all 
patients with AS are admitted to hospital. Secondly, it is po-
ssible that in the case of some ASs the questionnaires might 
not have been sent to the NHF. Thirdly, we could not estimate 
the number of stroke-related deaths that had occurred prior to 
the patient’s arrival at hospital, and therefore the true hospita-
lised incidence of stroke might be underestimated. Fourthly, 
we only analysed the questionnaire data and the information 
those questionnaires contained. As a result, human error could 
have occurred. Fifthly, the data was anonymous so we could 
not analyse the trends for strokes. 
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